Victory Capital Management Inc Savara Inc Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

A detailed history of Victory Capital Management Inc transactions in Savara Inc stock. As of the latest transaction made, Victory Capital Management Inc holds 140,010 shares of SVRA stock, worth $422,830. This represents 0.0% of its overall portfolio holdings.

Number of Shares

140,010

Previous 130,830 7.02%

Holding current value

$422,830

Previous $527,000 12.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$3.96 - $5.07 $36,352 - $46,542	9,180 Added 7.02%	140,010 $593,000
Q2 2024 Aug 05, 2024	BUY	$3.66 - $5.34 $478,837 - $698,632	130,830 New	130,830 $527,000
Q2 2023 Jul 27, 2023	BUY	$1.69 - $3.24 $20,474 - $39,252	12,115 New	12,115 $38,000
Q2 2022 Aug 01, 2022	SELL	$1.1 - $1.58 $64 - $93	-59 Reduced 0.53%	11,055 $17,000
Q1 2022 May 04, 2022	SELL	$1.05 - $1.36 $331 - $429	-316 Reduced 2.76%	11,114 $13,000
Q4 2021 Feb 07, 2022	BUY	$1.04 - $1.34 $697 - $899	671 Added 6.24%	11,430 $14,000
Q3 2021 Nov 02, 2021	SELL	$1.18 - $1.64 $404 - $562	-343 Reduced 3.09%	10,759 $15,000
Q2 2021 Aug 03, 2021	SELL	$1.51 - $2.29 $4,566 - $6,924	-3,024 Reduced 21.41%	11,102 $19,000
Q1 2021 May 04, 2021	BUY	$1.17 - $2.33 $16,527 - $32,913	14,126 New	14,126 $29,000
Q2 2020 Aug 07, 2020	SELL	$1.8 - $3.05 $13,545 - $22,951	-7,525 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$1.91 - $4.08 $2,800 - $5,981	1,466 Added 24.2%	7,525 $16,000
Q4 2019 Feb 04, 2020	BUY	$0.71 - $4.91 $107 - $746	152 Added 2.57%	6,059 $16,000
Q3 2019 Nov 12, 2019	BUY	$2.16 - $3.2 $12,759 - $18,902	5,907 New	5,907 $16,000

Others Institutions Holding SVRA

# of Institutions

129

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $344M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Savara Inc Transaction History